KO
Adaptive Biotechnologies Pipeline
| Drug | Indication | Phase |
|---|---|---|
| clonoSEQ | Multiple Myeloma (Bone Marrow) | Approved |
| TCR Therapeutics Platform | Cancer, Autoimmune, Infectious Disease | Discovery |
| Antibody Therapeutics Platform | Infectious Disease, Cancer | Discovery |
| SARS-CoV-2 Neutralizing Antibodies | COVID-19 | Discovery |
Leadership Team at Adaptive Biotechnologies
CR
Chad Robins
Chief Executive Officer, Co-founder, Chairman of the Board
HR
Harlan Robins
Chief Scientific Officer & Co-founder
JR
Julie Rubinstein
President & Chief Operating Officer
SB
Sharon Benzeno
Chief Commercial Officer, Immune Medicine
FL
Francis Lo
Chief People Officer
SB
Susan Bobulsky
Chief Commercial Officer, MRD
MP
Mary Pat Lancelotta
Senior Vice President, MRD BioPharma
PN
Peter Neupert
Board Member
MG
Michelle Griffin
Board Member
RH
Robert Hershberg
Board Member